MPN

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

A new analysis of the myMPN Patient Registry has led to some exciting new discoveries, according to researchers.

Any action, larger or small, can make a major impact in the lives of patients with a myeloproliferative neoplasm.

After her daughter was diagnosed, Celia Miltz founded the Friends of ET Research.

Angela Fleischman, M.D., Ph.D., is particularly excited for improvements in treating early-stage disease.

After realizing how little awareness there was about MPNs, one advocate looked to his TV background to help.

Jaden Persaud knows firsthand how a MPN diagnosis can affect a family's life.

In this week's episode of the CURE Talks Cancer podcast, hear from some of our recent MPN Heroes.

The 2018 MPN Champion Awards celebrate Canadian patients, caregivers and supporters.

Understanding the disease and treatments are key aspects of being a patient advocate, explained MPN Hero Marcy Worthington.

For this MPN Hero, helping patients came naturally, she said.

To address the lack of information on this younger subset of patients, an international team of researchers analyzed a large dataset from 29 hospital centers in 12 countries.

More than 40 percent of patients with a myeloproliferative neoplasm reported that they were unsatisfied with their current pain management strategy.

In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.

For this episode of the CURE Talks Cancer podcast, we spoke with Scott Hamilton, an Olympic gold medalist, cancer survivor and founder of the Scott Hamilton CARES Foundation

At the MPN Heroes Event, Olympic skater Scott Hamilton discusses importance of advocacy and research.

While Jakafi has been providing promising outcomes so far, there are still some side effects that patients and providers should look out for.

A Danish study demonstrated smokers were 2.5 times more likely to develop a myeloproliferative neoplasm compared with their non-smoking counterparts.

Two treatments that may help patients with a potentially deadly blood cancer live longer and prevent the incidence of thrombosis (blood clots) are being underused.

After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.

For many patients with polycythemia vera, hydroxyurea is a beneficial first-line treatment. But that’s not the case for everyone. One expert discusses which drugs should be used next.

Understanding the type of MPN can affect how care is carried out and how well it may work.

Diagnosing and treating the disease before it turns into AML is a key area of study, said Srdan Verstovsek, M.D., Ph.D., medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.